scholarly journals Clinical characteristics and risk factors for mortality in COVID-19 inpatients in Birjand, Iran: a single-center retrospective study

2021 ◽  
Vol 26 (1) ◽  
Author(s):  
Ghodsiyeh Azarkar ◽  
Freshteh Osmani
Keyword(s):  
Risk Factors ◽  
Platelet Count ◽  
Protein Level ◽  
Clinical Characteristics ◽  
Single Center ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Risk Of Death ◽  
Survivor Group ◽  
Epidemiological Characteristics

Abstract Background The coronavirus disease 2019(COVID-19) has affected mortality worldwide. The Cox proportional hazard (CPH) model is becoming more popular in time-to-event data analysis. This study aimed to evaluate the clinical characteristics in COVID-19 inpatients including (survivor and non-survivor); thus helping clinicians give the right treatment and assess prognosis and guide the treatment. Methods This single-center study was conducted at Hospital for COVID-19 patients in Birjand. Inpatients with confirmed COVID-19 were included. Patients were classified as the discharged or survivor group and the death or non-survivor group based on their outcome (improvement or death). Clinical, epidemiological characteristics, as well as laboratory parameters, were extracted from electronic medical records. Independent sample T test and the Chi-square test or Fisher’s exact test were used to evaluate the association of interested variables. The CPH model was used for survival analysis in the COVID-19 death patients. Significant level was set as 0.05 in all analyses. Results The results showed that the mortality rate was about (17.4%). So that, 62(17%) patients had died due to COVID-19, and 298 (83.6%) patients had recovered and discharged. Clinical parameters and comorbidities such as oxygen saturation, lymphocyte and platelet counts, hemoglobin levels, C-reactive protein, and liver and kidney function, were statistically significant between both studied groups. The results of the CPH model showed that comorbidities, hypertension, lymphocyte counts, platelet count, and C-reactive protein level, may increase the risk of death due to the COVID-19 as risk factors in inpatients cases. Conclusions Patients with, lower lymphocyte counts in hemogram, platelet count and serum albumin, and high C-reactive protein level, and also patients with comorbidities may have more risk for death. So, it should be given more attention to risk management in the progression of COVID-19 disease.

scholarly journals Survival analysis and risk factors in COVID-19 patients

2021 ◽  
pp. 1-15
Author(s):  
Wen Lu ◽  
Shuhui Yu ◽  
Hailing Liu ◽  
Lihua Suo ◽  
Kuanyin Tang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Platelet Count ◽  
Survival Analysis ◽  
Blood Cell ◽  
Serum Albumin ◽  
Protein Level ◽  
Lymphocyte Count ◽  
Clinical Characteristics ◽  
C Reactive Protein ◽  
Reactive Protein

ABSTRACT BACKGROUND: The aim of this study is to evaluate the clinical characteristics and outcomes in 2019 novel coronavirus patients and to help clinicians perform correct treatment and evaluate prognosis and guide the treatment. METHODS: 239 patients who were diagnosed with COVID-19 were included in this study. Patients were divided into the improvement group and the death group according to their outcome (improvement or death).Clinical characteristics and laboratory parameters were collected from medical records. Continuous variables were tested by independent sample T test, and categorical variables were analyzed by chi-square test or Fisher exact test. Cox proportional hazard regression model was used for survival analysis in death patients. The time-dependent AUC curves based on white blood cell count, lymphocyte count, white blood cell, lymphocyte count, neutrophil counts age, blood urea nitrogen and C-reactive protein were plotted. RESULTS: Efficacy evaluation indicated that 99 patients (41.4%) had deteriorated, and 140 patients (58.6%) had improved. Oxygen saturation, hemoglobin levels, infection-related indicators, lymphocyte and platelets counts, C-reactive protein, serum albumin, liver and kidney function and lactate dehydrogenase in improvement group were statistically significant between the improvement and death groups. Survival analysis revealed that comorbidities, lymphocyte counts, platelet count, serum albumin, C-reactive protein level and renal dysfunction may be risk factors in patients with COVID-19. CONCLUSION: Patients with comorbidities, lower lymphocyte counts in hemogram, platelet count and serum albumin, high C-reactive protein level and renal dysfunctionmay have higher risk to death. More attention should be givento risk management in the progression of COVID-19.

scholarly journals Clinical Characteristics and Survival Analysis in Frequent Alcohol Consumers With COVID-19

2021 ◽  
Vol 8 ◽  
Author(s):  
Ricardo Wesley Alberca ◽  
Paula Ordonhez Rigato ◽  
Yasmim Álefe Leuzzi Ramos ◽  
Franciane Mouradian Emidio Teixeira ◽  
Anna Cláudia Calvielli Branco ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Immune Responses ◽  
Social Practice ◽  
Death Rate ◽  
Clinical Characteristics ◽  
Systemic Disease ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Excessive Consumption

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can generate a systemic disease named coronavirus disease–2019 (COVID-19). Currently, the COVID-19 pandemic has killed millions worldwide, presenting huge health and economic challenges worldwide. Several risk factors, such as age, co-infections, metabolic syndrome, and smoking have been associated with poor disease progression and outcomes. Alcohol drinking is a common social practice among adults, but frequent and/or excessive consumption can mitigate the anti-viral and anti-bacterial immune responses. Therefore, we investigated if patients with self-reported daily alcohol consumption (DAC) presented alteration in the immune response to SARS-CoV-2. We investigated 122 patients with COVID-19 (101 male and 46 females), in which 23 were patients with DAC (18 men and 5 women) and 99 were non-DAC patients (58 men and 41 women), without other infections, neoplasia, or immunodeficiencies. Although with no difference in age, patients with DAC presented an increase in severity-associated COVID-19 markers such as C-reactive protein (CRP), neutrophil count, and neutrophil-to-lymphocyte ratio. In addition, patients with DAC presented a reduction in the lymphocytes and monocytes counts. Importantly, the DAC group presented an increase in death rate in comparison with the non-DAC group. Our results demonstrated that, in our cohort, DAC enhanced COVID-19-associated inflammation, and increased the number of deaths due to COVID-19.

C-reactive protein level predicts 30-day mortality and bleeding in patients with venous thromboembolism: A prospective single-center study

2020 ◽  
Vol 155 (2) ◽  
pp. 51-56
Author(s):  
Pablo Demelo-Rodríguez ◽  
Francisco Galeano-Valle ◽  
Almudena Marcelo-Ayala ◽  
Eduardo Fernández-Carracedo ◽  
Alicia Cuenca-Zarzuela ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Protein Level ◽  
Single Center ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Single Center Study ◽  
Center Study

scholarly journals Clinical Characteristics and Outcomes of First 100 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2) Patients: A Single Center Experience

2020 ◽  
Vol 2 (3) ◽  
Author(s):  
Kashif Naeem ◽  
Vinod Choondal ◽  
Mahmoud Hamouri ◽  
Ahmed Abbas ◽  
Sreevidya Machingal ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Severe Acute Respiratory Syndrome ◽  
Clinical Characteristics ◽  
World Health ◽  
Categorical Variables ◽  
Single Center ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
The World ◽  
Normal Chest

Since December 2019, the world has witnessed the Coronavirus disease caused by the Severe Acute Respiratory Syndrome Coronavirus-2, which has been declared a pandemic by the World Health Organization in March 2020. We share our initial experience at a center in Dubai, UAE, with a diverse ethnic population and present the clinical characteristics of the first 100 laboratory-confirmed coronavirus disease patients. In this retrospective, single center study, we included all adult (≥12 years old) laboratory-confirmed COVID-19 patients who presented at Al Kuwait Hospital, Dubai, UAE between 21 February 2020 and 15 April 2020. We extracted data on the demograhics, clinical presentation, laboratory and imaging results, treatment, complications and outcomes from the electronic medical records. Results are expressed as counts and percentages for categorical variables, and mean (with range) for continuous variables. A total of one hundred patients were studied. Mean age was 44 years (range 13-82 years); 16% were aged more than 60 years. 69% were males. Most of the patients (41%) belonged to South Asia, while 33% belonged to the Middle East. 21% were diabetics, 20% were hypertensives, 10% were active smokers and 6% were known cases of asthma/chronic obstructive lung disease. Upon admission, fever (46%) and dry cough (41%) were the most common symptoms, while  24% were asymptomatic on admission. Mean duration of symptoms before hospital admission was 5.1 days (range 1-14 days). Upon admission, 8% had low platelets, 7% had lymphopenia, 61% had high C-reactive protein, 48% had high ferritin, 37% had high lactate dehydrogenase, and 31% had high D-dimers. 63% had normal chest radiography upon presentation. Computed tomography chest showed ground glass opacification in 80%, consolidation in 21% while 14% had ill defined patchy opacities. All lesions were located peripherally and 79% had bilateral involvement with predominantly lower lobe disease. 8% had critical illness. Chloroquine/hydroxychloroquine (93%) and the protease inhibitor lopinavir-ritonavir (86%) were the most commonly prescribed treatment. 8% needed non-invasive ventilation and 7% were intubated and ventilated invasively. 7% developed acute repiratory distress syndrome, 5% went into septic shock and needed vasopressor support, 2% developed acute cardiac injury, 17% had acute kidney injury, 11% had acute liver injury and 2% developed disseminated intravascular coagulation. Almost half of the patients (49%) were declared recovered after having two negative COVID-19 PCR tests while 5% died. We concluded that the Coronavirus disease 2019 (COVID-19) presents with different clinical characteristics in the UAE with an ethnic diverse background. Majority affected were young, males and diabetic. One-fourth were asymptomatic on admission, while fever and dry cough were the most common symptoms. High C-reactive protein and ferritin on admission was common. Most of the patients had normal chest radiograph on admission, while computed tomography chest showed the characteristic findings in over two-thirds. Almost half of our patients recovered while 5% died. This is an intial experience only and increased patient cohort will provide further information.

C-reactive protein level predicts 30-day mortality and bleeding in patients with venous thromboembolism: A prospective single-center study

2020 ◽  
Vol 155 (2) ◽  
pp. 51-56
Author(s):  
Pablo Demelo-Rodríguez ◽  
Francisco Galeano-Valle ◽  
Almudena Marcelo-Ayala ◽  
Eduardo Fernández-Carracedo ◽  
Alicia Cuenca-Zarzuela ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Protein Level ◽  
Single Center ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Single Center Study ◽  
Center Study

scholarly journals Risk factors of severe cases with COVID-19: a meta-analysis

2020 ◽  
Vol 148 ◽  
Author(s):  
Mingchun Ou ◽  
Jieyun Zhu ◽  
Pan Ji ◽  
Hongyuan Li ◽  
Zhimei Zhong ◽  
...  
Keyword(s):  
Risk Factors ◽  
Platelet Count ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Severe Disease ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Electronic Search ◽  
Low Platelet Count ◽  
D Dimer

Abstract Our study aimed to systematically analyse the risk factors of coronavirus disease 2019 (COVID-19) patients with severe disease. An electronic search in eight databases to identify studies describing severe or critically ill COVID-19 patients from 1 January 2020 to 3 April 2020. In the end, we meta-analysed 40 studies involving 5872 COVID-19 patients. The average age was higher in severe COVID-19 patients (weighted mean difference; WMD = 10.69, 95%CI 7.83–13.54). Patients with severe disease showed significantly lower platelet count (WMD = −18.63, 95%CI −30.86 to −6.40) and lymphocyte count (WMD = −0.35, 95%CI −0.41 to −0.30) but higher C-reactive protein (CRP; WMD = 42.7, 95%CI 31.12–54.28), lactate dehydrogenase (LDH; WMD = 137.4, 95%CI 105.5–169.3), white blood cell count（WBC), procalcitonin（PCT）, D-dimer, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine（Cr）. Similarly, patients who died showed significantly higher WBC, D-dimer, ALT, AST and Cr but similar platelet count and LDH as patients who survived. These results indicate that older age, low platelet count, lymphopenia, elevated levels of LDH, ALT, AST, PCT, Cr and D-dimer are associated with severity of COVID-19 and thus could be used as early identification or even prediction of disease progression.

scholarly journals Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

2020 ◽  
Vol 5 (3) ◽  
pp. 279-284 ◽  
Author(s):  
Yanan Li ◽  
Man Li ◽  
Mengdie Wang ◽  
Yifan Zhou ◽  
Jiang Chang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cerebrovascular Disease ◽  
Management Strategy ◽  
Clinical Characteristics ◽  
C Reactive Protein ◽  
Laboratory Findings ◽  
Reactive Protein ◽  
Negative Prognostic Factor ◽  
History Of ◽  
New Onset

Background and purposeCOVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Apart from respiratory complications, acute cerebrovascular disease (CVD) has been observed in some patients with COVID-19. Therefore, we described the clinical characteristics, laboratory features, treatment and outcomes of CVD complicating SARS-CoV-2 infection.Materials and methodsDemographic and clinical characteristics, laboratory findings, treatments and clinical outcomes were collected and analysed. Clinical characteristics and laboratory findings of patients with COVID-19 with or without new-onset CVD were compared.ResultsOf 219 patients with COVID-19, 10 (4.6%) developed acute ischaemic stroke and 1 (0.5%) had intracerebral haemorrhage. COVID-19 with new onset of CVD were significantly older (75.7±10.8 years vs 52.1±15.3 years, p<0.001), more likely to present with severe COVID-19 (81.8% vs 39.9%, p<0.01) and were more likely to have cardiovascular risk factors, including hypertension, diabetes and medical history of CVD (all p<0.05). In addition, they were more likely to have increased inflammatory response and hypercoagulable state as reflected in C reactive protein (51.1 (1.3–127.9) vs 12.1 (0.1–212.0) mg/L, p<0.05) and D-dimer (6.9 (0.3–20.0) vs 0.5 (0.1–20.0) mg/L, p<0.001). Of 10 patients with ischemic stroke; 6 received antiplatelet treatment with aspirin or clopidogrel; and 3 of them died. The other four patients received anticoagulant treatment with enoxaparin and 2 of them died. As of 24 March 2020, six patients with CVD died (54.5%).ConclusionAcute CVD is not uncommon in COVID-19. Our findings suggest that older patients with risk factors are more likely to develop CVD. The development of CVD is an important negative prognostic factor which requires further study to identify optimal management strategy to combat the COVID-19 outbreak.

Sign in / Sign up

Export Citation Format

Share Document